TrialBlood2020

Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial.

Madan Jagasia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.